{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:00:13Z","timestamp":1783551613745,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neuropharm.2024.110065","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T03:16:54Z","timestamp":1720927014000},"page":"110065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions"],"prefix":"10.1016","volume":"258","author":[{"given":"Thi Mai","family":"Loan Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Guilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Defaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Mendez-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Etting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine C.","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn N.","family":"Highland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Zanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lovett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruin","family":"Moaddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Corruble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis J.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0320-4880","authenticated-orcid":false,"given":"Alain M.","family":"Gardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110065_bib1","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.biopsych.2017.01.002","article-title":"What's the buzz about hydroxynorketamine? Is it the history, the story, the debate, or the promise?","volume":"81","author":"Abdallah","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00216-012-6470-0","article-title":"An automated method for measurement of methoxetamine in human plasma by use of turbulent flow on-line extraction coupled with liquid chromatography and mass spectrometric detection","volume":"405","author":"Abe","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.neuropharm.2024.110065_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jneumeth.2004.04.042","article-title":"Rapid and precise method to locate microdialysis probe implantation in the rodent brain","volume":"140","author":"Bert","year":"2004","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2024.110065_bib4","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/s41380-022-01673-w","article-title":"Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search","volume":"27","author":"Bonaventura","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.116.235838","article-title":"Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters","volume":"359","author":"Can","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.110065_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","volume":"23","author":"Cavalleri","year":"2018","journal-title":"Mol. Psychiatr."},{"issue":"9","key":"10.1016\/j.neuropharm.2024.110065_bib60","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.06.033","article-title":"(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray","volume":"139","author":"Chou","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib9","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.biopsych.2016.06.029","article-title":"Antidepressant actions of ketamine versus hydroxynorketamine","volume":"81","author":"Collingridge","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/WNR.0000000000001131","article-title":"(2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans","volume":"29","author":"Collo","year":"2018","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2024.110065_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.neuron.2009.04.017","article-title":"Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety\/depression","volume":"62","author":"David","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.110065_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpba.2018.01.039","article-title":"Rapid analysis of glutamate, glutamine and GABA in mice frontal cortex microdialysis samples using HPLC coupled to electrospray tandem mass spectrometry","volume":"152","author":"Defaix","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.neuropharm.2024.110065_bib13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.npp.1300433","article-title":"Effects of chronic fluoxetine in animal models of anxiety and depression","volume":"29","author":"Dulawa","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib14","series-title":"Crossover Trial for Treatment-Resistant Major Depression 45","first-page":"1398","article-title":"Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled","author":"Farmer","year":"2020"},{"key":"10.1016\/j.neuropharm.2024.110065_bib15","article-title":"Rapid anxiolytic effects of serotonin type 4 receptor agonist, RS67333, and classical benzodiazepine, diazepam, are mediated by projections from the prefrontal cortex to the dorsal raphe nucleus","author":"Faye","year":"2019","journal-title":"Biol. Psychiatr."},{"issue":"48","key":"10.1016\/j.neuropharm.2024.110065_bib16","doi-asserted-by":"crossref","first-page":"18150","DOI":"10.1074\/jbc.RA119.008837","article-title":"Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2","volume":"294","author":"Fred","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2024.110065_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1073\/pnas.1814709116","article-title":"Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine","volume":"116","author":"Fukumoto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2024.110065_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","article-title":"Molecular pharmacology and neurobiology of rapid-acting antidepressants","volume":"59","author":"Gould","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2024.110065_bib19","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/jps.20963","article-title":"Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)","volume":"96","author":"Gupta","year":"2007","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.neuropharm.2024.110065_bib20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/acschemneuro.1c00761","article-title":"Hydroxynorketamine pharmacokinetics and antidepressant behavioral effetcts of (2,6)- and (5R-methyl-(2R,6R- hydroxynorketamines","volume":"13","author":"Highland","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110065_bib21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.npp.1301399","article-title":"Behavioral effects of chronic fluoxetine in BALB\/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor","volume":"33","author":"Holick","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.28.5.648","article-title":"Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans","volume":"28","author":"Humphrey","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.neuropharm.2024.110065_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13030432","article-title":"Characterization of 3-hydroxyeticyclidine (3-HO-PCE) metabolism in human liver microsomes and biological samples using high-resolution mass spectrometry","volume":"13","author":"Larabi","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.neuropharm.2024.110065_bib24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2024.110065_bib25","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/npp.2013.332","article-title":"Rapid anxiolytic effects of a 5-HT(4) receptor agonist are mediated by a neurogenesis-independent mechanism","volume":"39","author":"Mendez-David","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fphar.2013.00124","article-title":"A method for biomarker measurements in peripheral blood mononuclear cells isolated from anxious and depressed mice: beta-arrestin 1 protein levels in depression and treatment","volume":"4","author":"Mendez-David","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110065_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.157","article-title":"The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats","volume":"3","author":"Moaddel","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.neuropharm.2024.110065_bib28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41380-018-0252-9","article-title":"Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies","volume":"24","author":"Moriguchi","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1476-5381.2012.01850.x","article-title":"Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice","volume":"168","author":"Nguyen","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110065_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109357","article-title":"Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory\/inhibitory synaptic activity","volume":"225","author":"Nguyen","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1213\/00000539-199807000-00039","article-title":"The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil","volume":"87","author":"Palkama","year":"1998","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2024.110065_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/clpt.2011.140","article-title":"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine","volume":"90","author":"Peltoniemi","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2024.110065_bib33","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.biopsych.2017.10.020","article-title":"Common neurotransmission recruited in (R,S)-Ketamine and (2r,6r)-hydroxynorketamine-induced sustained antidepressant-like effects","volume":"84","author":"Pham","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuropharm.2016.05.010","article-title":"Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB\/cJ mice","volume":"112","author":"Pham","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib35","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2024.110065_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejps.2016.05.022","article-title":"Pharmacokinetics\/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis","volume":"92","author":"Santos","year":"2016","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.neuropharm.2024.110065_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28124771","article-title":"Synthesis and receptor binding studies of alpha 5 GABA(A)R selective novel imidazodiazepines targeted for psychiatric and cognitive disorders","volume":"28","author":"Sharmin","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2024.110065_bib38","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22084","article-title":"Effects of a ketamine metabolite on synaptic NMDAR function","volume":"546","author":"Suzuki","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.110065_bib39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/bdd.1888","article-title":"Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats","volume":"35","author":"Uchida","year":"2014","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.neuropharm.2024.110065_bib40","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.biopsych.2013.04.025","article-title":"Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses","volume":"74","author":"Voleti","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib41","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1007\/s11064-017-2240-x","article-title":"Effect of efflux transporter inhibition on the distribution of fluconazole in the rat brain","volume":"42","author":"Wang","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2024.110065_bib42","article-title":"NMDAR-independent, cAMP-dependent antidepressant actions of ketamine","author":"Wray","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib43","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","article-title":"(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice","volume":"43","author":"Yamaguchi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41380-021-01092-3","article-title":"Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications","volume":"27","author":"Yan","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib45","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2r,6r)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib46","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1023\/A:1016048100712","article-title":"Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis","volume":"13","author":"Yang","year":"1996","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.neuropharm.2024.110065_bib47","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/mp.2017.239","article-title":"Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit","volume":"23","author":"Yao","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107667","article-title":"Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission","volume":"157","author":"Ye","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110065_bib49","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/bph.14683","article-title":"(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses","volume":"176","author":"Zanos","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110065_bib50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.110065_bib51","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.biopsych.2016.08.039","article-title":"Reply to: antidepressant actions of ketamine versus hydroxynorketamine","volume":"81","author":"Zanos","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110065_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2125.2012.04198.x","article-title":"Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression","volume":"74","author":"Zhao","year":"2012","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082400234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082400234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:07:50Z","timestamp":1738591670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082400234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":54,"alternative-id":["S002839082400234X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110065","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.03.587904","asserted-by":"object"}]},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110065"}}